You are here


Mammozol is an insecticidal repellent and an inhibitor of enzymes. It is part of a group of hormonal antagonists and other similar drugs.





L02BG03 Anastrozole

Indications of mammozol

It is indicated for:

  • common form of breast cancer in postmenopausal women (except those who have discovered the estrogen-inactive form of cancer, except when the patient showed a positive response to the drug tamoxifen substance);
  • adjuvant treatment of invasive breast cancer estrogen-positive type (during the menopause at the early stages of the disease);
  • additional treatment of early-stage breast cancer estrogen-positive type during menopause in women who are between 2-3 years of age was conducted adequate treatment with tamoxifen.

Release form

Produced in tablet form, 14 pieces per blister plate. Inside one package there are 2 such blisters.


Anastrozole is a strong, highly selective aromatase inhibitor. During postmenopause, the production of estradiol in women is often carried out in a transformative form - inside the peripheral tissues - from androstenedione to estrone (aromatase enzyme takes part in this). Further, estrone is converted into the substance estradiol. Reduction of the circulating estradiol in the blood has a medicinal effect on women who suffer from breast cancer. The drug in a daily dose of 1 mg causes in women during postmenopause, a decrease in the rates of estradiol by 80%.

Anastrozole has no activity against androgens, progestogens, and estrogens.

In a daily dose of up to 10 mg, the drug does not affect the release of aldosterone with cortisol, the level of which was measured before, and also after standard testing using stimulation of ACTH. Therefore, it is not necessary to carry out substitution treatment with the use of corticosteroids.


The drug is quickly absorbed after oral administration, reaching peak plasma values after 2 hours (in case of fasting). In the case of reception, along with food, the suction rate decreases slightly, but its degree remains the same. Individual changes in the rates of absorption should not have a drug-significant effect on the equilibrium plasma concentration of drugs in the case of daily use of the 1st pill.

About 90-95% of the equilibrium drug index is reached after 7 days after drug use. There is no evidence that the pharmacokinetics of the active substance depends on the size of the dosage or the time of administration. Synthesis of anastrozole with a plasma protein is 40%.

Extensive metabolism of the active component is observed in women who are in the postmenopausal period. The very process of metabolism occurs by means of hydroxylation, N-dealkylation, and also glucuronization.

The excretion of the substance is rather slow, the plasma half-life is 40-50 hours. Urine excreted less than 10% of the dosage (unchanged substance) - this occurs during the 72 hours after taking drugs. The products of decay are mostly excreted in the urine. The main decay product (triazole), which can be found in urine, as well as plasma, is not an aromatase inhibitor.

Use of mammozol during pregnancy

Mammozol can not be used by pregnant women, as well as during lactation.


Among the contraindications of drugs:

  • severe intolerance to anastrozole or other components of the drug;
  • premenopausal period;
  • Kidney failure in severe degree (QC values are less than 20 ml / minute);
  • disorders in the work of the liver (severe or moderate degree);
  • combination with the substance tamoxifen or estrogen;
  • childhood.

Side effects of mammozol

Often, adverse reactions to the use of drugs became hot flashes, asthenia and (less common reaction). Only rarely develop symptoms of allergy (hives, angioedema or anaphylaxis).

Among other side effects are the following:

  • NA bodies: in most cases, there are headaches (usually moderate or light character), and besides carpal tunnel syndrome. Occasionally it may develop drowsiness (typically also in moderate or mild);
  • Gastrointestinal organs: usually nausea (moderate or light); more rarely observed vomiting, and moderate or light character;
  • subcutaneous layer with the skin: mainly hair thinning can be observed (weakly or moderately expressed) and the appearance of a rash on the skin (light or moderate forms). Sporadically developing Stevens-Johnson syndrome or erythema multiforme;
  • ODA agencies: mainly observed pain in the joints or the reduction of their motor activity (degree of expression - moderate or weak);
  • digestive system and metabolism processes: may occasionally develop anorexia (in the form of light), and furthermore hypercholesterolemia moderate or mild severity;
  • mammary gland and the reproductive organs: usually observed vaginal mucous dryness (moderate or light). Occasionally observed light or moderate bleeding from the vagina (usually this type of violation was observed in women with advanced stage breast cancer in the first few weeks after changing forms of treatment - a treatment using hormones to use Mammozola). If the bleeding does not stop, it is required to conduct an additional inspection.

Due to the fact that anastrozole lowers circulating estrogen indicators, may weaken the bone mineral density in the structure, with the result that individual women may intensify the risk of fracture.

Increased GGT values, as well as alkaline phosphatase is observed rarely.

Dosing and administration

For adults (also elderly women) the dose is equal to a one-time (per day) oral intake of 1 mg of the drug.

Correct the size of the doses for women suffering from mild or mild disorders in the work of the kidneys, as well as mild disorders of the hepatic function, is not necessary.

At the beginning of treatment at an early stage of the pathology, the duration of the treatment course using Mammozol is usually 5 years.


There is only limited information regarding clinical cases of development of a random overdose. The size of a single dose of the drug, which is capable of causing life-threatening abnormalities, has not been established.

The drug does not have a specific antidote, in the event of a disorder, symptomatic therapy is required. In the process of eliminating violations, it is necessary to take into account the possibility that the patient took not only Mammozol. If it is conscious, it is recommended to induce vomiting. In addition, dialysis can become an effective method for overdose, since anastrozole is poorly synthesized with protein. Also, general supportive treatment and constant monitoring of the work of life-critical systems and organs are required.

Interactions with other drugs

Clinical tests for interaction with cimetidine and antipyrin substances have shown that when anastrozole is combined with other drugs, there is likely to be no medically significant effect caused by the hemoprotein P450.

Anastrozole slows the action of P450 1A2 hemoprotein as well as 2C8 / 9 with 3A4 in in vitro tests, although clinical trials of combining with warfarin have demonstrated that 1 mg of anastrozole almost does not interfere with the metabolism of elements that are metabolized by the hemoprotein P450. There is no significant interaction between anastrozole and phosphonates.

A study of the safety data collected during the clinical trials revealed no information about the significant interaction of drugs in women who combined anastrozole with other commonly prescribed drugs.

Estrogens are not allowed to combine with anastrozole, because these drugs have opposite pharmacological properties.

It is also not possible to combine Mammozol with tamoxifen, since it can weaken the drug efficacy of anastrozole.

Storage conditions

The medicine must be kept in a place inaccessible to small children. The temperature values are not more than 30 ° C.

Shelf life

Mammozol allowed to use during the 3 years since the release of the drug.

Found an error? Select it and press Ctrl + Enter.

Share on social networks


To simplify the perception of information, this instruction for use of the drug "Mammozol" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.

Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.

You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.